Detalhe da pesquisa
1.
Immunology of relapse and remission in multiple sclerosis.
Annu Rev Immunol
; 32: 257-81, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24438352
2.
Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM.
Nature
; 603(7900): 321-327, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35073561
3.
Elevated α5 integrin expression on myeloid cells in motor areas in amyotrophic lateral sclerosis is a therapeutic target.
Proc Natl Acad Sci U S A
; 120(32): e2306731120, 2023 08 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37523555
4.
T cell deletional tolerance restricts AQP4 but not MOG CNS autoimmunity.
Proc Natl Acad Sci U S A
; 120(30): e2306572120, 2023 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37463205
5.
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
N Engl J Med
; 387(8): 704-714, 2022 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36001711
6.
Defective sphingosine 1-phosphate receptor 1 (S1P1) phosphorylation exacerbates TH17-mediated autoimmune neuroinflammation.
Nat Immunol
; 14(11): 1166-72, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24076635
7.
NAD+ metabolism drives astrocyte proinflammatory reprogramming in central nervous system autoimmunity.
Proc Natl Acad Sci U S A
; 119(35): e2211310119, 2022 08 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35994674
8.
Risk of severe COVID-19 infection among adults with prior exposure to children.
Proc Natl Acad Sci U S A
; 119(33): e2204141119, 2022 08 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35895714
9.
COVID-19 therapeutics: Challenges and directions for the future.
Proc Natl Acad Sci U S A
; 119(15): e2119893119, 2022 04 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35385354
10.
Mobilization of innate and adaptive antitumor immune responses by the RNP-targeting antibody ATRC-101.
Proc Natl Acad Sci U S A
; 119(19): e2123483119, 2022 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35507878
11.
Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches.
Proc Natl Acad Sci U S A
; 118(9)2021 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33627407
12.
Targeting deoxycytidine kinase improves symptoms in mouse models of multiple sclerosis.
Immunology
; 168(1): 152-169, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35986643
13.
Reduced development of COVID-19 in children reveals molecular checkpoints gating pathogenesis illuminating potential therapeutics.
Proc Natl Acad Sci U S A
; 117(40): 24620-24626, 2020 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32883878
14.
Autoantibodies against central nervous system antigens in a subset of B cell-dominant multiple sclerosis patients.
Proc Natl Acad Sci U S A
; 117(35): 21512-21518, 2020 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32817492
15.
Mixed results with modulation of TH-17 cells in human autoimmune diseases.
Nat Immunol
; 11(1): 41-4, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20016509
16.
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
Mult Scler
; 28(12): 1944-1962, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35765217
17.
DNA threads released by activated CD4+ T lymphocytes provide autocrine costimulation.
Proc Natl Acad Sci U S A
; 116(18): 8985-8994, 2019 04 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-30988194
18.
Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial.
Proc Natl Acad Sci U S A
; 116(17): 8463-8470, 2019 04 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-30962374
19.
Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials.
Eur J Neurol
; 28(11): 3722-3730, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34292643
20.
HDL-bound sphingosine-1-phosphate restrains lymphopoiesis and neuroinflammation.
Nature
; 523(7560): 342-6, 2015 Jul 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-26053123